Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platinum plus dose-dense temozolomide for recurrent malignant glioma
ChiCTR-OPC-14005508Phase 2Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Dec 2014
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, carboplatin and temozolomide in malignant glioma and glioma, sponsored by The First Hospital of Jilin University. Primary endpoints: overall survival and therapeutic response. Planned start Dec 2014; status: not yet recruiting.
02
Drugs
cisplatincarboplatintemozolomide
03
Conditions
malignant gliomaglioma
Beyond the preview
Go deeper on ChiCTR-OPC-14005508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-14005508.